Fulgent Genetics (FLGT) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

FLGT · Stock Price

USD 15.11-3.45 (-18.59%)

Market Cap: $431.5M

Historical price data

Market Cap: $431.5MPatents: 1Founded: 2011HQ: El Monte, United States

Sector Ranking#76 in Diagnostics & Precision Medicine #76 in Oncology (General)

Overview

Founded in 2011, Fulgent Genetics has grown from a focused genetic testing lab into a comprehensive precision medicine company, merging a vast diagnostic services business with an emerging therapeutic development arm. Its strategic acquisitions, including Bako Diagnostics and StrataDx, have expanded its capabilities into anatomic pathology and solidified its market position. The company's mission is to develop flexible and affordable diagnostics and therapeutics to improve patient outcomes across oncology, rare diseases, and reproductive health.

OncologyRare DiseasesReproductive HealthInfectious Disease

Technology Platform

Proprietary integrated platform combining high-throughput clinical NGS diagnostics with a novel nanoencapsulation and targeted therapy platform for cancer drug development.

Funding History

3

Total raised:$40M

IPO$30MUndisclosedSep 28, 2016

Series A$8MUndisclosedJun 15, 2013

Seed$2MUndisclosedJun 15, 2011

Opportunities

The primary opportunity lies in synergizing its vast diagnostic data and clinician network with its novel therapeutic platform to create a closed-loop precision medicine model.

Success in developing targeted nanoencapsulation cancer therapies could unlock high-margin revenue streams and significant valuation upside.

Risk Factors

Key risks include reimbursement pressure on diagnostic services, the high failure rate inherent in early-stage drug development, and execution risks in integrating recent acquisitions.

The company's valuation is sensitive to clinical progress in its therapeutic pipeline.

Competitive Landscape

Fulgent faces intense competition in diagnostics from large labs (Quest, LabCorp) and specialized genomics firms. Its therapeutic platform will compete with numerous biopharma companies. Its integrated diagnostic-therapeutic strategy is a key potential differentiator.